Takeaways Novartis is using this initiative to deepen its positioning as a “health equity partner” to government and community groups in Canada, with a fresher focus on women and gender‑diverse ...
Takeaways Dr. Reddy’s is using this Canada launch to cement itself as an early global player in generic GLP‑1 injectables, showing it can move from approval to market in days and supply at ...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
Takeaways: This authorization makes iStatis the first rapid point‑of‑care HBsAg test cleared in both Canada and North America, giving frontline providers a 15‑minute to...
Takeaways: BC’s decision makes REVESTIVE a province‑funded option for both adult and pediatric Short Bowel Syndrome patients who depend on parenteral support, align...
Takeaways: CELYSTRA is being set up as a dedicated Canadian “importer–operator” for advanced rare‑disease drugs, starting with RNA therapeutics. It’s led by senior ex‑big‑pha...
Takeaways: Kisunla adds a new money‑maker for Lilly in Canada, but real sales will depend on how fast the system can diagnose patients early and pay for the drug. Because testing and speci...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
